Copyright © 2009 Scott N. Pinchot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. R. S. Sippel, M. Kunnimalaiyaan, and H. Chen, “Current management of medullary thyroid cancer,” Oncologist, vol. 13, no. 5, pp. 539–547, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
2. D. W. Ball, “Medullary thyroid cancer: monitoring and therapy,” Endocrinology and Metabolism Clinics of North America, vol. 36, no. 3, pp. 823–837, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
3. D. W. Ball, “Medullary thyroid cancer: therapeutic targets and molecular markers,” Current Opinion in Oncology, vol. 19, no. 1, pp. 18–23, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
4. A. Machens, J. Ukkat, S. Hauptmann, and H. Dralle, “Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis,” Archives of Surgery, vol. 142, no. 3, pp. 289–294, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
5. J. F. Moley, T. C. Lairmore, and J. E. Phay, “Hereditary endocrinopathies,” Current Problems in Surgery, vol. 36, no. 9, pp. 653–762, 1999. View at Scopus
6. H. Chen, J. R. Roberts, D. W. Ball, et al., “Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection,” Annals of Surgery, vol. 227, no. 6, pp. 887–895, 1998. View at Publisher · View at Google Scholar · View at Scopus
7. E. Kebebew, S. Kikuchi, Q.-Y. Duh, and O. H. Clark, “Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer,” Archives of Surgery, vol. 135, no. 8, pp. 895–901, 2000. View at Scopus
8. J. F. Moley, “Medullary thyroid cancer,” Surgical Clinics of North America, vol. 75, no. 3, pp. 405–420, 1995. View at Scopus
9. H. Chen, M. Kunnimalaiyaan, and J. J. Van Compel, “Medullary thyroid cancer: the functions of Raf-1 and human achaete-scute homologue-1,” Thyroid, vol. 15, no. 6, pp. 511–521, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
10. M. Kunnimalaiyaan, K. Traeger, and H. Chen, “Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells,” American Journal of Physiology, vol. 289, no. 4, pp. G636–G642, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
11. M. Kunnimalaiyaan and H. Chen, “The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors?” Anti-Cancer Drugs, vol. 17, no. 2, pp. 139–142, 2006.
12. E. K. Nakakura, V. R. Sriuranpong, M. Kunnimalaiyaan, et al., “Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 7, pp. 4350–4356, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
13. G. H. Jossart and R. F. Grossman, “Tumor oncogenesis,” in Textbook of Endocrine Surgery, O. H. Clark, Q.-Y. Duh, and L. McGrew, Eds., WB Saunders, Philadelphia, Pa, USA, 1997.
14. S. Manié, M. Santoro, A. Fusco, and M. Billaud, “The RET receptor: function in development and dysfunction in congenital malformation,” Trends in Genetics, vol. 17, no. 10, pp. 580–589, 2001. View at Publisher · View at Google Scholar · View at Scopus
15. A. Machens, P. Niccoli-Sire, J. Hoegel, et al., “Early malignant progression of hereditary medullary thyroid cancer,” New England Journal of Medicine, vol. 349, no. 16, pp. 1517–1525, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
16. M. Santoro and F. Carlomagno, “Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer,” Nature Clinical Practice Endocrinology and Metabolism, vol. 2, no. 1, pp. 42–52, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
17. F. Carlomagno, D. Vitagliano, T. Guida, et al., “ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases,” Cancer Research, vol. 62, no. 24, pp. 7284–7290, 2002. View at Scopus
18. S. R. Wedge, D. J. Ogilvie, M. Dukes, et al., “ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration,” Cancer Research, vol. 62, no. 16, pp. 4645–4655, 2002. View at Scopus
19. S. A. Wells, J. E. Gosnell, R. F. Gagel, et al., “Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial,” Journal of Clinical Oncology, vol. 25, supplement, no. 18, 2007.
20. S. Kim, Y. D. Yazici, G. Calzada, et al., “Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice,” Molecular Cancer Therapeutics, vol. 6, no. 6, pp. 1785–1792, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
21. D. W. Kim, Y. S. Jo, H. S. Jung, et al., “An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 10, pp. 4070–4076, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
22. T. Hoelting, A. E. Siperstein, O. H. Clark, and Q.-Y. Duh, “Epidermal growth factor enhances proliferation, migration, and invasion of follicular and papillary thyroid cancer in vitro and in vivo,” Journal of Clinical Endocrinology and Metabolism, vol. 79, no. 2, pp. 401–408, 1994. View at Publisher · View at Google Scholar · View at Scopus
23. Q.-Y. Duh, E. T. Gum, P. L. Gerend, S. E. Raper, and O. H. Clark, “Epidermal growth factor receptors in normal and neoplastic thyroid tissue,” Surgery, vol. 98, no. 6, pp. 1000–1007, 1985. View at Scopus
24. H. Masuda, A. Sugenoya, S. Kobayashi, Y. Kasuga, and F. Iida, “Epidermal growth factor receptor on human thyroid neoplasms,” World Journal of Surgery, vol. 12, no. 5, pp. 616–622, 1988. View at Scopus
25. L. Gorla, P. Mondellini, G. Cuccuru, et al., “Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements,” Molecular Carcinogenesis, vol. 48, no. 3, pp. 220–231, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
26. J. Folkman, “Tumor angiogenesis: therapeutic implications,” New England Journal of Medicine, vol. 285, no. 21, pp. 1182–1186, 1971. View at Scopus
27. E. E. W. Cohen, L. S. Rosen, E. E. Vokes, et al., “Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study,” Journal of Clinical Oncology, vol. 26, no. 29, pp. 4708–4713, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
28. S. I. Sherman, L. J. Wirth, J.-P. Droz, et al., “Motesanib diphosphate in progressive differentiated thyroid cancer,” New England Journal of Medicine, vol. 359, no. 1, pp. 31–42, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
29. P. Cohen and S. Frame, “The renaissance of GSK3,” Nature Reviews Molecular Cell Biology, vol. 2, no. 10, pp. 769–776, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
30. M. Kunnimalaiyaan, A. M. Vaccaro, M. A. Ndiaye, and H. Chen, “Inactivation of glycogen synthase kinase-3$\beta$, a downstream target of the Raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells,” Molecular Cancer Therapeutics, vol. 6, no. 3, pp. 1151–1158, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
31. T. Kadesch, “Notch signaling: the demise of elegant simplicity,” Current Opinion in Genetics and Development, vol. 14, no. 5, pp. 506–512, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
32. K. Yoon and N. Gaiano, “Notch signaling in the mammalian central nervous system: insights from mouse mutants,” Nature Neuroscience, vol. 8, no. 6, pp. 709–715, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
33. Y. Y. Tee, A. J. Lowe, C. A. Brand, and R. T. Judson, “Fine-needle aspiration may miss a third of all malignancy in palpable thyroid nodules: a comprehensive literature review,” Annals of Surgery, vol. 246, no. 5, pp. 714–720, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
34. M. Kunnimalaiyaan and H. Chen, “Tumor suppressor role of notch-1 signaling in neuroendocrine tumors,” Oncologist, vol. 12, no. 5, pp. 535–542, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
35. M. Kunnimalaiyaan, A. M. Vaccaro, M. A. Ndiaye, and H. Chen, “Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells,” Journal of Biological Chemistry, vol. 281, no. 52, pp. 39819–39830, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
36. D. Y. Greenblatt, M. A. Cayo, J. T. Adler, et al., “Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells,” Annals of Surgery, vol. 247, no. 6, pp. 1036–1040, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
37. L. Ning, D. Y. Greenblatt, M. Kunnimalaiyaan, and H. Chen, “Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells,” Oncologist, vol. 13, no. 2, pp. 98–104, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
38. S. N. Pinchot, S. C. Pitt, R. S. Sippel, M. Kunnimalaiyaan, and H. Chen, “Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors,” Current Opinion in Investigational Drugs, vol. 9, no. 6, pp. 576–582, 2008. View at Scopus
39. R. S. Sippel, J. E. Carpenter, M. Kunnimalaiyaan, and H. Chen, “The role of human achaete-scute homolog-1 in medullary thyroid cancer cells,” Surgery, vol. 134, no. 6, pp. 866–873, 2003. View at Publisher · View at Google Scholar · View at Scopus
40. A. Vaccaro, H. Chen, and M. Kunnimalaiyaan, “In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer,” Anti-Cancer Drugs, vol. 17, no. 7, pp. 849–853, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
41. R. K. Ravi, E. Weber, M. McMahon, et al., “Activated Raf-1 causes growth arrest in human small cell lung cancer cells,” Journal of Clinical Investigation, vol. 101, no. 1, pp. 153–159, 1998. View at Scopus
42. R. K. Ravi, A. Thiagalingam, E. Weber, M. McMahon, B. D. Nelkin, and M. Mabry, “Raf-1 causes growth suppression and alteration of neuroendocrine markers in DMS53 human small-cell lung cancer cells,” American Journal of Respiratory Cell and Molecular Biology, vol. 20, no. 4, pp. 543–549, 1999. View at Scopus
43. J.-I. Park, C. J. Strock, D. W. Ball, and B. D. Nelkin, “The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway,” Molecular and Cellular Biology, vol. 23, no. 2, pp. 543–554, 2003. View at Publisher · View at Google Scholar · View at Scopus
44. L. Ning, M. Kunnimalaiyaan, and H. Chen, “Regulation of cell-cell contact molecules and the metastatic phenotype of medullary thyroid carcinoma by the Raf-1/MEK/ERK pathway,” Surgery, vol. 144, no. 6, pp. 920–925, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
45. C. A. Hall-Jackson, P. A. Eyers, P. Cohen, et al., “Paradoxical activation of Raf by a novel Raf inhibitor,” Chemistry and Biology, vol. 6, no. 8, pp. 559–568, 1999. View at Publisher · View at Google Scholar · View at Scopus
46. J. J. Van Gompel, M. Kunnimalaiyaan, K. Holen, and H. Chen, “ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells,” Molecular Cancer Therapeutics, vol. 4, no. 6, pp. 910–917, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
47. M. Kunnimalaiyaan, M. Ndiaye, and H. Chen, “Neuroendocrine tumor cell growth inhibition by ZM336372 through alterations in multiple signaling pathways,” Surgery, vol. 142, no. 6, pp. 959–964, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
48. R. Malaguarnera, V. Vella, R. Vigneri, and F. Frasca, “p53 family proteins in thyroid cancer,” Endocrine-Related Cancer, vol. 14, no. 1, pp. 43–60, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
49. B. Saltman, B. Singh, C. V. Hedvat, V. B. Wreesmann, and R. Ghossein, “Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression,” Surgery, vol. 140, no. 6, pp. 899–906, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
50. H. A. Sheikh, M. Tometsko, L. Niehouse, et al., “Molecular genotyping of medullary thyroid carcinoma can predict tumor recurrence,” American Journal of Surgical Pathology, vol. 28, no. 1, pp. 101–106, 2004. View at Publisher · View at Google Scholar · View at Scopus
51. F. Moretti, S. Nanni, and A. Pontecorvi, “Molecular pathogenesis of thyroid nodules and cancer,” Best Practice and Research Clinical Endocrinology and Metabolism, vol. 14, no. 4, pp. 517–539, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
52. F. S. Wyllie, N. R. Lemoine, E. D. Williams, and D. Wynford-Thomas, “Structure and expression of nuclear oncogenes in multi-stage thyroid tumorigenesis,” British Journal of Cancer, vol. 60, no. 4, pp. 561–565, 1989. View at Scopus
53. P. Terrier, Z.-M. Sheng, M. Schlumberger, et al., “Structure and expression of c-myc and c-fos proto-oncogenes in thyroid carcinomas,” British Journal of Cancer, vol. 57, no. 1, pp. 43–47, 1988. View at Scopus